Premium
Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second‐line therapy with BCR‐ABL1 ≤10% and no major molecular response
Author(s) -
Bonecker Simone,
Carvalho Gabriela,
Dobbin Jane,
Zalcberg Ilana,
Schaffel Rony
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15611
Subject(s) - nilotinib , medicine , dasatinib , imatinib mesylate , imatinib , tyrosine kinase inhibitor , oncology , adverse effect , myeloid leukemia , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom